Healthcare Industry News: diabetes
News Release - September 18, 2017
ARKRAY launches ADAMS(TM) A1c HA-8180V System for hemoglobin A1c testingEDINA, Minn., Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- U.S. ARKRAY, Inc. (ARKRAY) announces the launch of the ADAMS™ A1c HA-8180V System for hemoglobin A1c testing. The system obtained FDA 510(k) clearance as an aid in the diagnosis and monitoring of individuals with diabetes.
The fully automated analyzer utilizes gold standard HPLC technology. Providing superior precision with CV's of one percent or lower offers clinicians confidence diagnosing and treating diabetes.
"We are excited to bring this technology to the U.S. market. The ADAMS A1c HA-8180V builds on proven expertise. The ADAMS brand has been used globally for decades. ARKRAY introduced the first fully automated HPLC HbA1c analyzer in 1981," said Shane Hawes, General Manager ARKRAY.
The system is simple to operate and generates results in ninety seconds. Calibration and maintenance are minimized with the integrated column and pre-filter. Hands-on time is reduced with primary tube cap-piercing sampling and no sample pre-treatment.
Early detection and treatment of diabetes can decrease the risk of developing long-term complications. The ADAMS A1c HA-8180V improves outcomes generating the quality results required to assess patient care.
U.S. ARKRAY, Inc. is a wholly owned subsidiary of ARKRAY, Inc. of Kyoto, Japan. ARKRAY, Inc. was founded in 1960 as Kyoto Daiichi Kagaku Inc. (KDK). ARKRAY is a global leader in urinalysis and continues to develop innovative diagnostic products including automated urinalysis and HbA1c systems. For more information, please visit www.arkrayusa.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.